Pharmacology, Toxicology and Pharmaceutical Science
Drug Safety
100%
Epidemiology
63%
Oral Contraceptive
42%
Selective Serotonin Reuptake Inhibitor
42%
Risk Communication
29%
Cisapride
21%
Pegaptanib
21%
Disease
21%
Orphan Drug
21%
Randomized Controlled Trial
21%
Hepatobiliary Disease
7%
Adverse Drug Reaction
7%
Adverse Event
7%
Injury
7%
Biological Product
7%
QT Prolongation
7%
MedDRA
7%
Toxic Injury
7%
Electronic Prescribing
5%
Pharmacovigilance
5%
Keyphrases
Safety-related Regulatory Action
42%
Direct Healthcare Professional Communication
27%
Safety Messages
21%
Professional Self
21%
Clinical Practice
21%
Malan Syndrome
21%
SMC1A
21%
Autistic Women
21%
Pegaptanib
15%
Black Box Warning
12%
Interrupted Time Series Design
12%
Health Advisory
12%
Drug Groups
9%
Elapsed Time
9%
Evaluation Board
7%
Medicine Evaluation
7%
NIPBL
7%
Orphan Drugs
6%
Safety Issues
6%
Public Health
6%
Unintended Consequences
6%
Interrupted Time Series
6%
Third Generation
6%
Selective Serotonin Reuptake Inhibitors
6%
Oral Contraceptives
6%
Drug Safety
6%
Confounding Factors
6%
Media Coverage
6%
Country Names
6%
Clinical Behavior
6%
Quality Aspects
6%
Design Analysis
6%
Specific Safety
6%
Publication Year
6%
Marketing Approval
6%
Medical Journals
5%
Cohesin Complex
5%
Medicine and Dentistry
Drug Safety
31%
De Lange Syndrome
21%
Randomized Controlled Trial
21%
Ambulatory Care
21%
Drug Use
21%
Pegaptanib
21%
Medicine
16%
Health Care Provider
10%
Cohort Effect
10%
Fisher Exact Test
8%
Risk Communication
8%
Facies
5%
Upper Limb
5%
Limb Malformation
5%
Molecular Diagnostics
5%
Diagnosis
5%
Care Planning
5%
Genetic Disorder
5%
Molecular Diagnosis
5%
Next Generation Sequencing
5%
Physical Disease by Body Function
5%
Cohesin
5%
